TY - JOUR
T1 - Systemic methotrexate induces spatial memory deficits and depletes cerebrospinal fluid folate in rats
AU - Li, Yan
AU - Vijayanathan, Veena
AU - Gulinello, Maria E.
AU - Cole, Peter D.
N1 - Funding Information:
We are thankful of the technical support of Zareen Mehmud. This work was supported in part by the Damon Runyon Cancer Research Foundation ( CI-16-03 ).
PY - 2010/1
Y1 - 2010/1
N2 - Purpose: Although most children with acute lymphoblastic leukemia (ALL) are cured, a subset manifests persistent, focal cognitive deficits. Methotrexate (MTX), a key component of leukemia treatment, is suspected to contribute to treatment-induced cognitive dysfunction. We sought to establish a rodent model in order to further investigate the underlying pathophysiology. Procedures: Intraperitoneal MTX was given to Long-Evans rats on two schedules: acute (250 mg/kg once during adulthood), or chronic (1 mg/kg twice weekly ×4 doses, beginning at postnatal day 15, then weekly ×6). Control rats were given saline injections on the same schedules. All male rats subsequently underwent behavioral testing designed to assess cognitive domains frequently impaired among children treated for ALL. Cerebrospinal fluid and serum folate concentrations were measured by HPLC. Findings: Both acute and chronic MTX administration produced spatial memory deficits, without significantly altering visual memory, general exploration, activity or motor coordination. MTX administration was also associated with a marked reduction in serum and CSF folate and a decrease in the ratio of CSF S-adenosylmethionine to S-adenosylhomocysteine. Conclusions: Similar to children treated for ALL, rats given systemic MTX develop focal cognitive deficits along with expected alterations in folate physiology.
AB - Purpose: Although most children with acute lymphoblastic leukemia (ALL) are cured, a subset manifests persistent, focal cognitive deficits. Methotrexate (MTX), a key component of leukemia treatment, is suspected to contribute to treatment-induced cognitive dysfunction. We sought to establish a rodent model in order to further investigate the underlying pathophysiology. Procedures: Intraperitoneal MTX was given to Long-Evans rats on two schedules: acute (250 mg/kg once during adulthood), or chronic (1 mg/kg twice weekly ×4 doses, beginning at postnatal day 15, then weekly ×6). Control rats were given saline injections on the same schedules. All male rats subsequently underwent behavioral testing designed to assess cognitive domains frequently impaired among children treated for ALL. Cerebrospinal fluid and serum folate concentrations were measured by HPLC. Findings: Both acute and chronic MTX administration produced spatial memory deficits, without significantly altering visual memory, general exploration, activity or motor coordination. MTX administration was also associated with a marked reduction in serum and CSF folate and a decrease in the ratio of CSF S-adenosylmethionine to S-adenosylhomocysteine. Conclusions: Similar to children treated for ALL, rats given systemic MTX develop focal cognitive deficits along with expected alterations in folate physiology.
KW - Cerebrospinal fluid
KW - Homocysteine
KW - Methotrexate
KW - S-adenosylhomocysteine
KW - S-adenosylmethionine
KW - Spatial memory
UR - http://www.scopus.com/inward/record.url?scp=72149134895&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=72149134895&partnerID=8YFLogxK
U2 - 10.1016/j.pbb.2009.10.008
DO - 10.1016/j.pbb.2009.10.008
M3 - Article
C2 - 19887080
AN - SCOPUS:72149134895
SN - 0091-3057
VL - 94
SP - 454
EP - 463
JO - Pharmacology Biochemistry and Behavior
JF - Pharmacology Biochemistry and Behavior
IS - 3
ER -